Expression of somatostatin receptor type 2 in colorectal cancer

Abstract

Abstract: AIM: To investigate the expression and role of somatostatin receptor subtype2 (SSR2) in the pathogenesis and progression of human colorectal cancer (CRC).METHODS: 37 cases of CRC in inpatients were identified and all tissue specimens of the cases after surgical resection immediately were selected.The tissue specimens including remote mucosa of tumors (10 cm beyond the tumor),adjacent mucosa of tumors(within 2 cm of the tumor),tumors.The expression of SSR2 mRNA in the specimens were detected by reverse transcription polymerase chain reaction(RT-PCR) and the positive rate and the expression in the specimens were analyzed.RESULTS: The SSR2 mRNA expression rate of the samples shows remote mucosa of tumor 100%(37/37),adjacent mucosa of tumor 91.9%(34/37) and tumor 83.8% (31/37). Compared with the nomal colorectal mucosae,the expression rate and expression intensity of tumor were decreased significantly (P=0.038, P=0.021). The significant correlation of SSR2 mRNA expression rate and intensity in tumor differentiation (P=0.021,P=0.013) and tumor stage (P=0.005,P=0.019) were found,while there was no significant correlation in the expression of SSR2 mRNA and other clinic pathological parameters such as age,sex,tumor size,site and the level of CEA in serum.CONCLUSION: The expression of SSR2 mRNA in tumor is decreased significantly. SSR2 mRNA expression rate and expression intensity of tumor are correlated with the tumor differentiation and stage,and SSR2 may play an important role in the pathogenesis and progression of CRC.

Key words: Colorectal cancer, Somatostatin receptor, Somatostatin receptor 2, RT-PCR

CLC Number:

R735. 34

CHENG Yuan-guang, WU Pei. Expression of somatostatin receptor type 2 in colorectal cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1100-1104.

References

[1] 吴佩, 闫竞一, 茆家定, 等. 胃泌素、生长抑素对大肠癌细胞周期的调控作用[J].中华实验外科杂志,2005, 22(12): 1586.
[2] 许小兵, 张晓华, 杨妙芳, 等. PTPeta介导生长抑素对SMMC7721生长抑制作用的实验研究[J]. 中国临床药理学与治疗学,2011,16(11): 1222-1226.
[3] Hagemeister A, Kittilson JD, Bergan HE, et al. Rainbow trout somatostatin receptor subtypes SSTR1A, SSTR1B, and SSTR2 differentially activate the ERK and PI3K signaling pathways in transfected cells[J]. J Mol Endocrinol, 2010, 45(5): 317-327.
[4] Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling[J]. Trends Endoerinol Metab,2010, 21(3): 123-133.
[5] Righi L, Volante M, Tacaglione V, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218'clinically aggressive' case[J]. Ann Oncol, 2010, 21(3): 548-555.
[6] Johnson MD, O'Connell MJ, Silberstein H, et al. Differential Expression of Somatostatin Receptors, P44/42 MAPK, and mTOR Activation in Medulloblastomas and Primitive Neuroectodermal Tumors[J]. Appl Immunohistochem Mol Morphol,2013 Feb 28. [Epub ahead of print]
[7] Msaouel P, Galanis E, Koutsilieris M.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology[J]. Expert Opin Investig Drugs,2009, 18(9):1297-1316.
[8] Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors[J]. J Clin Invest, 1994, 93(3): 1321-1325.
[9] Nie GY, Wang J, Li Y, et al. Construction and application of a multispecific competitor to quantify mRNA of matrix metallopro-teinases and their tissue inhibitors in small human biopsies[J]. J Biochem Biophys Methods,1999, 40(3): 81-99.
[10] Garinis GA, Manolis EN, Spanakis NE, et al. High frequency of concomitant nm23-H1 and E-cadherin transcriptional inactivation in primary non- inheriting colorectal carcinomas[J]. J Mol Med,2003, 81(4): 256-263.
[11] Smitha MC, Maggi M, Orlando C. Somatostatin receptors in non-endocrine tumours[J]. Dig Liver Dis,2004, 36(Suppl 1): S78-85.
[12] Colucci R, Blandizzi C, Ghisu N, et al. Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 down regulation[J]. Br J Pharmacol,2008, 155(2): 198-209.
[13] Dy DY, Whitehead RH, Morris DL. SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer[J]. Cancer Res,1992, 52(4): 917-923.
[14] Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial[J]. World J Gastroenterol,2007, 13(23): 3164-3170.
[15] Raggi CC, Cianchi F, Valanzano R, et al. Prognostic value of somatostatin receptor subtype 2 expression in colorectal cancer[J]. Regul Pept,2005, 132(1/2/3): 23-26.
[16] Smith MC, Maggi M,Orlando C. Somatostatin receptors in non-endocrine tumours[J]. Dig Liver Dis,2004, 36(Suppl 1): S78-S85.
[17] Casini Raggi C, Calabrò A, Renzi D, et al. Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa[J]. Clin Cancer Res,2002, 8(2): 419-427.
[18] Evangelou I, Petraki C, Msaouel P, et al. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer[J]. Eur J Clin Invest,2012, 42(7): 777-783.